| CASE REPORT |
|
| Year : 2014 | Volume
: 9
| Issue : 4 | Page : 163-164 |
|
|
Targeted therapy in triple-negative breast cancer: A case series
Mehrdad Payandeh1, Edris Sadeghi2, Masoud Sadeghi3
1 Department of Hematology and Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 Department of Nursing, Borujerd Branch, Islamic Azad University, Borujerd, Iran
3 Department of Pharmacology, Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Correspondence Address:
Mehrdad Payandeh
Department of Hematology and Oncology, Kermanshah University of Medical Sciences, Kermanshah
Iran
  | Check |
DOI: 10.4103/1858-5000.153032 
|
|
|
At least 20% of breast cancers are characterized by triple-negative receptor status (negative for estrogen receptor, progesterone receptor, and HER2). Human epidermal growth-factor receptor (EGFR) is a member of the EGFR/ErbB/HER family of Type I transmembrane tyrosine kinase receptors. Nine patients had TN-EGFR-positive with metastatic breast cancer (MBC). EGFR positivity was defined as staining in >10% of tumor cells by Immunohistochemistry. In total, nine patients were enrolled that the mean age was 46.7 years. All patients were from Kurdish ethnicity in west of Iran. Patients received erlotinib 150 mg daily. This suggests there may be a subset of TN, EGFR-positive MBC for whom EGFR-directed therapy may be suitable or that the natural history of their disease was indolent. Future studies to determine molecular and clinical profiles of patients likely to benefit from EGFR-tyrosine kinase inhibitor therapy.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Next article
